Department of Urology, New York Medical College, Valhalla, New York, USA.
Int J Gen Med. 2009 Jul 30;2:15-7. doi: 10.2147/ijgm.s4948.
Superficial bladder tumors are the most prevalent form of bladder cancers and transurethral resection is the primary surgical modality for those tumors. However, nearly 65% of patients will have tumor recurrence in five years while about 15% will have progression to muscle invasion. Thus, the primary therapeutic aim is to prevent multiple recurrences and progression to a more advanced, invasive disease. We here report an 87-year-old white male patient with invasive bladder cancer who received an unconventional oral regimen of D-fraction, the bioactive extract of Maitake mushroom (Grifola frondosa), following endoscopic transurethral resection of bladder tumor. Despite a high risk for disease recurrence, follow-up yet indicated no clinical evidence of progression of residual disease or recurrence of invasive cancer. It has been nearly two years but the patient remains remarkably well and appears to be in remission. To our knowledge, this is the first and only case report of possible disease remission in a bladder cancer patient after the two-year follow-up of D-fraction regimen, so that further studies with long terms are required for drawing a relevant conclusion. Nevertheless, it is conceivable that D-fraction is a natural agent that may have clinical implications in patients with superficial bladder tumors.
表浅性膀胱癌是最常见的膀胱癌类型，经尿道膀胱肿瘤切除术是治疗此类肿瘤的主要手术方式。然而，近 65%的患者在五年内会出现肿瘤复发，约 15%的患者会进展为肌肉浸润。因此，主要的治疗目标是预防多次复发和进展为更晚期、侵袭性疾病。我们在此报告一例 87 岁白人男性患者，患有浸润性膀胱癌，在接受经尿道膀胱肿瘤电切术后，接受了非常规的口服 D 分馏物（舞茸提取物）治疗。尽管存在疾病复发的高风险，但随访并未显示残留疾病进展或浸润性癌症复发的临床证据。目前已经将近两年了，但患者仍然状态良好，似乎处于缓解期。据我们所知，这是首例也是唯一一例在接受 D 分馏物治疗两年后膀胱癌患者可能出现疾病缓解的病例报告，因此需要进行长期的进一步研究以得出相关结论。然而，可以想象的是，D 分馏物是一种天然药物，可能对表浅性膀胱癌患者具有临床意义。
